Literature DB >> 2201426

Immunohistochemical study of melanocytic nevus and malignant melanoma with monoclonal antibodies against S-100 subunits.

K H Cho1, K Hashimoto, Y Taniguchi, T Pietruk, R J Zarbo, T An.   

Abstract

Immunohistochemical localization of S-100 protein alpha and beta subunits in the cells of melanocytic nevi and malignant melanomas was studied by using monoclonal antibodies directed against each subunit. Although polyclonal anti-S-100 reactivities have been demonstrated uniformly in all nevus cells and melanoma cells, monoclonal anti-S-100 alpha and anti-S-100 beta reactivities were either absent or rarely found in ordinary junctional nevi or junctional nests of ordinary compound nevi. However, in the junctional nests of dysplastic junctional nevi and junctional components of dysplastic compound nevi, monoclonal anti-S-100 alpha reactivity become more frequent, whereas monoclonal anti-S-100 beta reactivity remains negative. In the superficial variety of melanomas such as superficial spreading melanoma and lentigo maligna melanoma, monoclonal anti-S-100 beta is nonreactive until vertical growth or invasiveness begins. Most nodular melanomas are positively stained with both monoclonal anti-S-100 alpha and anti-S-100 beta. It is suggested that monoclonal anti-S-100 alpha can be an indicator of active junctional nevus of melanocytic nevi and the reactivity with monoclonal anti-S-100 beta may be related to vertical progression of superficial spreading melanomas and lentigo maligna melanomas.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2201426     DOI: 10.1002/1097-0142(19900815)66:4<765::aid-cncr2820660428>3.0.co;2-m

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Serum levels of S-100 protein and 5-S-cysteinyldopa as markers of melanoma progression.

Authors:  T Bánfalvi; K Gilde; M Boldizsár; T Kremmer; S Ottó
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

2.  Clinical relevance of molecular staging for melanoma: comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma.

Authors:  W Li; A Stall; S C Shivers; J Lin; F Haddad; J Messina; L F Glass; G Lyman; D S Reintgen
Journal:  Ann Surg       Date:  2000-06       Impact factor: 12.969

3.  Biomarkers: the useful and the not so useful--an assessment of molecular prognostic markers for cutaneous melanoma.

Authors:  Bonnie E Gould Rothberg; David L Rimm
Journal:  J Invest Dermatol       Date:  2010-06-17       Impact factor: 8.551

4.  Evaluation of new putative tumor markers for melanoma.

Authors:  G Miliotes; G H Lyman; C W Cruse; C Puleo; P A Albertini; D Rapaport; F Glass; N Fenske; T Soriano; C Cuny; N Van Voorhis; D Reintgen
Journal:  Ann Surg Oncol       Date:  1996-11       Impact factor: 5.344

5.  Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma.

Authors:  X Wang; R Heller; N VanVoorhis; C W Cruse; F Glass; N Fenske; C Berman; J Leo-Messina; D Rappaport; K Wells
Journal:  Ann Surg       Date:  1994-12       Impact factor: 12.969

6.  The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma.

Authors:  J M Bonfrer; C M Korse; O E Nieweg; E M Rankin
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

Review 7.  Established and Emerging Biomarkers in Cutaneous Malignant Melanoma.

Authors:  Stamatina Verykiou; Robert A Ellis; Penny E Lovat
Journal:  Healthcare (Basel)       Date:  2014-01-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.